|Malignant atrophic papulosis (Köhlmeier-Degos disease) - a review.|
|Jump to Full Text|
|PMID: 23316694 Owner: NLM Status: MEDLINE|
|EPIDEMIOLOGY: Less than 200 cases have been described in the literature. The first manifestation of MAP usually occurs between the 20th and 50th year of life.
CLINICAL DESCRIPTION: The cutaneous clinical picture is almost pathognomonic. The histology is not consistent but in most cases it shows a wedge-shaped connective tissue necrosis in the deep corium due to a thrombotic occlusion of the small arteries. In the systemic variant, manifestations mostly occur at the intestine and central nervous system.
ETIOLOGY: The etiopathogenesis of the disease remains unknown, a genetic predisposition may occur. Vasculitis, coagulopathy or primary dysfunction of the endothelial cells have been implicated.
DIAGNOSTIC METHODS: Diagnosis is only based on the characteristic skin lesions. DIFFERRENTIAL DIAGNOSIS: It depends on the clinical presentation of MAP, but systemic lupus erythematosus and other connective tissue diseases need to be considered.
MANAGEMENT: No effective treatment exists for the systemic manifestations, while compounds that facilitate blood perfusion have achieved a partial regression of the skin lesions in single cases.
PROGNOSIS: An apparently idiopathic, monosymptomatic, cutaneous, benign variant and a progressive, visceral one with approx. 50% lethality within 2-3 years have been reported. Systemic manifestations can develop years after the occurrence of skin lesions leading to bowel perforation and peritonitis, thrombosis of the cerebral arteries or massive intracerebral hemorrhage, meningitis, encephalitis, radiculopathy, myelitis.
|Athanasios Theodoridis; Evgenia Makrantonaki; Christos C Zouboulis|
Related Documents :
|24426394 - Acute urinary retention and obstipation: a rare cause….
23119654 - Tuberculous otitis media-are we missing it ?
17721384 - Value of toxoplasma gondii detection in one hundred thirty-three placentas for the diag...
20127594 - oesophageal perforation: a retrospective analysis of aetiology, diagnosis and therapy
2121344 - Percutaneous treatment of hydatid cysts (echinococcus granulosus).
23008784 - Plasmablastic lymphoma of gingiva mimicking a reactive lesion: a case report.
|Type: Journal Article; Review Date: 2013-01-14|
|Title: Orphanet journal of rare diseases Volume: 8 ISSN: 1750-1172 ISO Abbreviation: Orphanet J Rare Dis Publication Date: 2013|
|Created Date: 2013-02-08 Completed Date: 2013-07-23 Revised Date: 2013-11-06|
Medline Journal Info:
|Nlm Unique ID: 101266602 Medline TA: Orphanet J Rare Dis Country: England|
|Languages: eng Pagination: 10 Citation Subset: IM|
|Departments of Dermatology, Venerology, Allergology and Immunology, Dessau Medical Center, Auenweg 38, Dessau, 06847, Germany.|
|APA/MLA Format Download EndNote Download BibTex|
Immunosuppressive Agents / therapeutic use
Malignant Atrophic Papulosis* / diagnosis, drug therapy, pathology
Journal ID (nlm-ta): Orphanet J Rare Dis
Journal ID (iso-abbrev): Orphanet J Rare Dis
Publisher: BioMed Central
Copyright ©2013 Theodoridis et al.; licensee BioMed Central Ltd.
Received Day: 3 Month: 9 Year: 2012
Accepted Day: 9 Month: 1 Year: 2013
collection publication date: Year: 2013
Electronic publication date: Day: 14 Month: 1 Year: 2013
Volume: 8First Page: 10 Last Page: 10
PubMed Id: 23316694
Publisher Id: 1750-1172-8-10
|Malignant atrophic papulosis (Köhlmeier-Degos disease) - A review|
|Athanasios Theodoridis1||Email: email@example.com|
|Evgenia Makrantonaki12||Email: firstname.lastname@example.org|
|Christos C Zouboulis1||Email: email@example.com|
1Departments of Dermatology, Venerology, Allergology and Immunology, Dessau Medical Center, Auenweg 38, Dessau, 06847, Germany
2Research Group Geriatrics, Charité Universitätsmedizin Berlin, Reinickendorfer Strasse 61, Berlin, 13347, Germany
The malignant atrophic papulosis (Köhlmeier-Degos disease; MAP) was described by Köhlmeier in 1941  and documented as a separate entity by Degos et al. one year later . Although MAP has been known for almost 70 years, its pathomechanism remains still obscure. As a result no treatment has been proven sufficient enough to cope with the disease.
It is a rare disease; until today less than 200 cases have been described in the literature. The first manifestation of MAP usually occurs between the 20th and 50th year of life [3,4], while single cases with MAP in newborns and children have also been described [5,6]. A genetic predisposition with an autosomal dominant trait has been suggested, since there has been reports about more frequently affected 1st degree relatives [7-9].
The following article presents an overview of MAP as well as a summary of the proposed theories of disease development. The exact knowledge of MAP research history may lead to new unexplored pathways and eventually to the discovery of the pathogenesis of this potentially lethal illness.
The diagnosis of MAP is based in the majority of the cases on the pathognomonic skin lesions. They are about 0.5-1 cm large papules with an atrophic porcelain-white centre and an erythematous, teleangiectatic rim mostly occurring on the trunk and the upper extremities [4,10] (Figures 1, 2). The lesions appear initially as small erythematous papules. After a few days the centre sinks and they start to demonstrate the characteristic morphology. Palms, soles, scalp and face are rarely involved. On the other hand, involvement of the internal organs, with multiple limited infarcts of the intestine and/or the central nervous system (CNS) as well as of other organs, such as the lungs (presenting as pleuritis and/or pericarditis) and the eyes, has also been reported [11-14].
Due to the markedly different prognosis between the apparently idiopathic cutaneous disease and MAP with systemic involvement, the first variant - in contrast to the latter "malignant" one - has been termed "benign atrophic papulosis" by some authors [15,16]. However, it is still unclear if these two forms can be unambiguously distinguished from each other, since systemic involvement can develop year after the occurrence of the skin lesions.
The so called "benign" form of the disease is characterized by the typical skin lesions, which persist over years or lifelong, without involvement of the inner organs . Several cases have exhibited signs of inheritance, especially between first-degree relatives [7,9]. The malignant variant is characterized by involvement of the skin and the inner organs, either occurring simultaneously or subsequently. The systemic manifestations can be followed in many cases by serious complications, namely bowel perforation and peritonitis as well as thrombosis of the cerebral arteries or massive cerebral hemorrhage, meningitis, encephalitis, radiculopathy, myelitis  leading to lethal course in approx. 50% of the patients within 2 to 3 years. Lung involvement can be followed by pleuritis and/or pericarditis [10,19,20]. The prognosis can also be influenced by the extent of these ischemic complications, which are the determinants of mortality [2,8,21]. An ocular involvement with affection of the eyelids, conjuctiva, retina, sclera and the choroid plexus, as well as the development of diplopia and ophthalmoplegia as secondary side effects of the neurologic involvement have also been described . The fact that a systemic involvement can develop suddenly, years after the occurrence of skin lesions, makes a regular medical follow-up of the patients necessary.
The diagnosis of MAP is a clinical one and can be supported by the histological findings. The classical histology shows a wedge-shaped connective tissue necrosis, due to thrombotic occlusion of the small arteries deep in the corium [20,23,24]. However, these characteristic features cannot be demonstrated in all cases . Harvell et al.  examined in a case report the histology of the lesions according to the duration of their existence. Early lesions have shown a superficial and deep perivascular lymphocytic infiltration, with distinct mucin deposition, which resembled lupus erythematosus. The fully developed lesions had more prominent changes in the dermoepidermal junction, with atrophy of the epidermis and an area of sclerosis in the papillary dermis. These characteristics could be compatible with a minimal variant of lichen sclerosus et atrophicans. The late lesions showed a wedge-shaped necrosis, sparse lymphocytes and markedly less mucin deposition in comparison to the early and fully developed lesions (Figure 3).
No specific alterations of laboratory parameters - if any - have been reported  and no markers exist, which could verify the diagnosis. However, a relative large percentage of the patients has been described to present defects of blood coagulation.
The etiology of MAP remains unexplained. There is a whole series of hypotheses but none of them could be proven yet. The 3 most reasonable suggested hypotheses about the pathophysiology of the disease are vasculitis, coagulopathy and primary dysfunction of the endothelial cells . Although heterogeneous the aforementioned etiological suggestions are not necessarily mutually exclusive. The simultaneous presence of various factors creating the appropriate conditions for the development of thrombosis should be considered.
Soter et al.  have proposed that inflammation of the vessels could act as a trigger factor for the development of MAP. This inflammation was evaluated as an initial stadium of the disease, as in the histological samples of patients with MAP did not always demonstrate inflammatory cells. Su et al.  described a “lymphocyte-associated necrotic vasculitis” as the most prominent cutaneous feature of the skin lesions. In addition, they observed an analogy between the disseminated vasculitic process of the disease and the skin lesions of some patients with lupus erythematosus, which seemed similar. Currently, Magro et al.  have reported prominent C5b-9 deposits in skin, gastrointestinal tract and brain vessels of 4 patients with MAP, who have died from the disease. All cases had evidence of high expression of interferon-α (based on tissue expression of MXA, a type I interferon-inducible protein), endothelial tubuloreticular inclusions, and an interferon gene signature in peripheral blood mononuclear cells. The MXA expression paralleled the pattern of C5b-9 deposition.
A thrombus deep in the dermis (stratum reticulare) is the primary event in MAP. The reduction of the blood flow and the resulting damage of the endothelial cells lead to deposition of mucin and aggregation of mononuclear cells . Several authors have observed fibrinolytic dysfunction in selected patients [21,31-33]. Stahl et al.  and Drucker  have described single patients who showed an increased platelet aggregation in vivo. Both patients responded very well on the treatment with platelet aggregation inhibitors, namely aspirin and dipyridamole. Black et al.  observed a complete loss of fibrinolysis around the small blood vessels, in the centre of old and new papules in skin lesions of patients with MAP. Vazquez-Doval et al.  and Olmos et al.  described an increase of the activity of plasminogen activator inhibitor-1, while Paramo et al.  found that the serum level of plasminogen was decreased in a patient with MAP. Alternatively, Englert et al. , Mauad et al.  and Farell et al.  treated single patients with positive lupus anticoagulant. In addition to that, Yoshikawa et al.  have described a persistent increase of the thrombin-antithrombin III complex and of plasmin-α-2 plasmin inhibitor complex. All these observations may provide an explanation for the pathogenesis of MAP. Currently, Meephansan et al.  observed strong staining of the infiltrating inflammatory cells in the perivascular, intravascular, and perineural areas in tissue samples from 2 MAP patients with stromal cell–derived factor (SDF)-1/CXCL12, which is secreted by bone-marrow stromal and endothelial cells, activates megakaryocyte precursors, and costimulates platelet activation.
Tribble et al.  supposed that an abnormal swelling and proliferation of the vascular endothelium could trigger cutaneous, intestinal and central nervous system thrombosis. Howard and Nishida [43,44] observed tubulo-reticular aggregates in the endothelial cells with the help of electron microscopy. Therefore, a viral or bacterial infection could act as a cause for the endothelial changes [43-45]. Other authors showed intracytoplasmic paramyxovirus-like inclusions in electron microscopy of skin specimens from patients with MAP [18,35]. However, no proof of paramyxovirus-DNA in skin biopsies of patients has been provided via polymerase chain reaction .
There is no uniformly effective therapy for MAP. Efforts with fibrinolytic and immunosuppressive therapeutic regimens like cyclosporine A, azathioprine, cyclophosphamide and corticosteroids have been mostly unsuccessful. Furthermore, there have been reported cases where MAP worsened during immunosupression [7,46]. Explorative treatment with eculizumab could not prevent the development or progression of systemic manifestations (personal communications), despite its reported initial effectiveness on skin and intestinal lesions [47,48]. Other therapeutic efforts with anticoagulants and compounds that facilitate blood perfusion, such as acetylosalicylic acid (aspirin), pentoxifylline, dipyridamole, ticlodipine and heparin, have achieved a partial regression of the skin lesions in single cases [4,11,28,34,39,49,50]. Therefore, these agents can be used as a first therapeutic approach on a newly diagnosed patient with MAP. Subcutaneous treprostinil has currently been tested successfully in a case with eculizumab-resistant MAP with intestinal and CNS manifestations (Dr. Lee S. Shapiro, Albany, NY, personal communication).
Since every diagnosed MAP case can potentially develop into the systemic, life-threatening variant, an annual follow-up is mandatory. This should include a clinical inspection of the skin combined with additional examinations, such as brain magnetic resonance tomography, gastroscopy and colonoscopy, as well as X-ray of the chest and abdominal ultrasound in order to assess the long-term prognosis.
MAP is a rare and potentially life-threatening disease. The prognosis highly depends on the development of systemic involvement. Most of the lethal courses are due to bowel perforation or CNS lesions and their consequences. The probability of a benign course increases with the duration of monosymptomatic cutaneous disease.
CNS: Central nervous system; MAP: Malignant atrophic papulosis.
The authors declare that they have no competing interests.
AT wrote the manuscript. AT, EM and CCZ read, revised and approved the final manuscript. EM and CCZ share senior authorship.
The work is dedicated to Mrs. Judith Calder, Degos Patients' Network, who has been a long-term motivator and supporter for the initiation and continuation of research in this rare disease.
|Köhlmeier W,Multiple Hautnekrosen bei Thrombangitis obliteransArch Dermatol Syph (Wien)Year: 1941181783792|
|Degos R,Delort J,Tricot R,Dermatite papulosqameuse atrophianteBull Soc Fr Derm SyphYear: 194249148150|
|Snow JL,Muller SA,Degos syndrome: malignant atrophic papulosisSemin DermatolYear: 19951429910510.1016/S1085-5629(05)80004-57640203|
|Vázquez-Doval FJ,Ruiz de Erenchun F,Páramo JA,Quintanilla E,Malignant atrophic papulosis. A report of two cases with altered fibrinolysis and platelet functionClin Exp DermatolYear: 199318544144410.1111/j.1365-2230.1993.tb02246.x8252767|
|Torrelo A,Sevilla J,Mediero IG,Candelas D,Zambrano A,Malignant atrophic papulosis in an infantBr J DermatolYear: 2002146591691810.1046/j.1365-2133.2002.04677.x12000397|
|Caviness VS Jr,Sagar P,Israel EJ,Mackool BT,Grabowski EF,Frosch MP,Case 38–2006: A 5-year-old boy with headache and abdominal painN Engl J MedYear: 2006355242575258410.1056/NEJMcpc06902917167141|
|Powell J,Bordea C,Wojnarowska F,Farrell AM,Morris PJ,Benign familial Degos disease worsening during immunosuppressionBr J DermatolYear: 1999141352452710.1046/j.1365-2133.1999.03050.x10583060|
|Katz SK,Mudd LJ,Roenigk HH Jr,Malignant atrophic papulosis (Degos' disease) involving three generations of a familyJ Am Acad DermatolYear: 1997373 Pt 14804849308565|
|Kisch LS,Bruynzeel DP,Six cases of malignant atrophic papulosis (Degos' disease) occurring in one familyBr J DermatolYear: 1984111446947110.1111/j.1365-2133.1984.tb06611.x6487548|
|Melnik B,Hariry H,Vakilzadeh F,Gropp C,Sitzer G,Maligne atrophische Papulose (Morbus Köhlmeier-Degos) Kein Ansprechen auf Interferon α-2a, Pentoxifyllin und AzetylsalizylsäureHautarztYear: 200253961862110.1007/s00105-002-0347-712207267|
|Vicktor C,Schultz-Ehrenburg U,Papulosis maligna atrophicans (Köhlmeier-Degos) Diagnose, Therapie, VerlaufHautarztYear: 200152873473710.1007/s00105017009211544947|
|Thomson KF,Highet AS,Penile ulceration in fatal malignant atrophic papulosis (Degos' disease)Br J DermatolYear: 200014361320132210.1046/j.1365-2133.2000.03911.x11122044|
|Metz J,Amschler A,Henke M,Morbus Degos (Papulosis atrophicans maligna)HautarztYear: 19803121081107399897|
|Thomas RK,Nithyanandam S,Rawoof BJ,Rajendran SC,Malignant atrophic papulosis. Report of a case with multiple ophthalmic findingsIndian J OphthalmolYear: 20035126026314601855|
|Mensing C,Mensing H,Papulosis maligna atrophicans Degos Nicht immer maligne!HautarztYear: 2002531424610.1007/s105-002-8047-811963222|
|Heymann WR,Degos disease: Considerations for reclassificationJ Am Acad DermatolYear: 200961350550610.1016/j.jaad.2009.03.02819700015|
|Habbema L,Kisch LS,Starink TM,Familial malignant atrophic papulosis (Degos' disease) - additional evidence for heredity and a benign courseBr J DermatolYear: 1986114113413510.1111/j.1365-2133.1986.tb02789.x3942684|
|Olmos L,Laugier P,Ultrastructure de la maladie de Degos: Apport d'un nouveau cas et revue de la litératureAnn Dermatol VenereolYear: 1977104280293889231|
|Atchabahian A,Laisné MJ,Riche F,Briard C,Nemeth J,Valleur P,Small bowel fistulae in Degos' disease: a case report and literature reviewAm J GastroenterolYear: 19969110220822118855750|
|Burg G,Vieluf D,Stolz W,Landthaler M,Braun-Falco O,Maligne atrophische Papulose (Morbus Köhlmeier-Degos)HautarztYear: 19894084804852676909|
|Daniel F,Foix C,Gray JM,Lartigue P,Samama M,Baviera E,Camilleri JP,Papulose atrophiante maligne avec insuffisance de la fibrinolyse sanguineAnn Dermatol VenereolYear: 198210997637647158924|
|Lee DA,Su WP,Liesegang TJ,Ophthalmic changes of Degos' disease (malignant atrophic papulosis)OphthalmologyYear: 19849132952996717915|
|Lipsker D,Goldsmith L, Katz S, Gilchrest B, Paller A, Leffell D, Wolff KMalignant atrophic papulosis (Degos disease)Fitzpatrick's Dermatology in General MedicineYear: 2012New York: McGraw-Hill20722076|
|Soter NA,Murphy GF,Mihm MC Jr,Lymphocytes and necrosis of the cutaneous microvasculature in malignant atrophic papulosis: a refined light microscope studyJ Am Acad DermatolYear: 19827562063010.1016/S0190-9622(82)70142-26754777|
|Grilli R,Soriano ML,Izquierdo MJ,Fariña MC,Martin L,Manzarbeitia F,Requena L,Panniculitis mimicking lupus erythematosus profundus: a new histopathologic finding in malignant atrophic papulosis (Degos disease)Am J DermatopatholYear: 199921436536810.1097/00000372-199908000-0001010446779|
|Harvell JD,Williford PL,White WL,Benign cutaneous Degos' disease: a case report with emphasis on histopathology as papules chronologically evolveAm J DermatopatholYear: 200123211612310.1097/00000372-200104000-0000611285406|
|Ball E,Newburger A,Ackerman AB,Degos' disease: a distinctive pattern of disease, chiefly of lupus erythematosus, and not a specific disease per seAm J DermatopatholYear: 200325430832010.1097/00000372-200308000-0000512876488|
|Su WP,Schroeter AL,Lee DA,Hsu T,Muller SA,Clinical and histologic findings in Degos' syndrome (malignant atrophic papulosis)CutisYear: 19853521311383884281|
|Magro CM,Poe JC,Kim C,Shapiro L,Nuovo G,Crow MK,Crow YJ,Degos disease: a C5b-9/interferon-α-mediated endotheliopathy syndromeAm J Clin PatholYear: 2011135459961010.1309/AJCP66QIMFARLZKI21411783|
|Magrinat G,Kerwin KS,Gabriel DA,The clinical manifestations of Degos' syndromeArch Pathol Lab MedYear: 198911343543622650651|
|Paramo JA,Rocha E,Cuesta B,Arejola JM,Montejo M,Aguirre J,Prieto J,Rocha Hernando E,Fibrinolysis in Degos' diseaseThromb HaemostYear: 19855437304089805|
|Roenigk HH Jr,Farmer RG,Degos' disease (malignant papulosis). Report of three cases with clues to etiologyJAMAYear: 196820671508151410.1001/jama.1968.031500700460074176652|
|Howsden SM,Hodge SJ,Herndon JH,Freeman RG,Malignant atrophic papulosis of Degos. Report of a patient who failed to respond to fibrinolytic therapyArch DermatolYear: 1976112111582158810.1001/archderm.1976.01630350056015791153|
|Stahl D,Thomsen K,Hou-Jensen J,Degos' disease treated with platelet-suppressive drugsLancetYear: 197728027464769139|
|Drucker CR,Malignant atrophic papulosis: response to antiplatelet therapyDermatologicaYear: 19901802909210.1159/0002479992178991|
|Black MM,Nishioka K,Levene GM,The role of dermal blood vessels in the pathogenesis of malignant atrophic papulosis (Degos' disease). A study of two cases using enzyme histochemical, fibrinolytic, electron-microscopical and immunological techniquesBr J DermatolYear: 197388321321910.1111/j.1365-2133.1973.tb07537.x4351422|
|Englert HJ,Hawkes CH,Boey ML,Derue GJ,Loizou S,Harris EN,Gharavi AE,Hull RG,Hughes GR,Degos' disease: association with anticardiolipin antibodies and the lupus anticoagulantBr Med J (Clin Res Ed)Year: 1984289644557610.1136/bmj.289.6445.576|
|Mauad T,De Fátima Lopes Calvo Tiberio I,Baba E,Andrade Junior DR,Lichtenstein A,Capelozzi VL,Sotto MN,Saldiva PH,Malignant atrophic papulosis (Degos' disease) with extensive cardiopulmonary involvementHistopathologyYear: 1996281848610.1046/j.1365-2559.1996.t01-1-258289.x8838127|
|Farrell AM,Moss J,Costello C,Fearfield LA,Woodrow D,Bunker CB,Benign cutaneous Degos' diseaseBr J DermatolYear: 1998139470871210.1046/j.1365-2133.1998.02474.x9892920|
|Yoshikawa H,Maruta T,Yokoji H,Takamori M,Yachie A,Torii Y,Degos' disease: radiological and immunological aspectsActa Neurol ScandYear: 199694535335610.1111/j.1600-0404.1996.tb07079.x8947289|
|Meephansan J,Komine M,Hosoda S,Tsuda H,Karakawa M,Murata S,Demitsu T,Ohtsuki M,Possible involvement of SDF-1/CXCL12 in the pathogenesis of Degos diseaseJ Am Acad Dermatol in press.|
|Tribble K,Archer ME,Jorizzo JL,Sanchez R,Solomon AR Jr,Gardner FH,Cavallo T,Malignant atrophic papulosis: absence of circulating immune complexes or vasculitisJ Am Acad DermatolYear: 1986152 Pt 23653693734185|
|Nishida S,Howard RO,Is Degos' disease of viral origin?LancetYear: 196817553120012014172305|
|Howard RO,Nishida S,A case of Degos' disease with electron microscopic findingsTrans Am Acad Ophthalmol OtolaryngolYear: 1969736109711125372076|
|Pati S,Muley SA,Grill MF,Coons S,Walker R,Post-streptococcal vasculopathy with evolution to Degos' diseaseJ Neurol SciYear: 20113001–215715921035145|
|Requena L,Farina C,Barat A,Degos disease in a patient with acquired immunodeficiency syndromeJ Am Acad DermatolYear: 1998385 Pt 28528569591802|
|Garrett-Bakelman F,DeSancho M,Magro C,C5b-9 is a potential effector in the pathophysiology of Degos disease; a case report of treatment with eculizumab (abstract)Year: 2010Jerusalem: International Society of Hematology poster 156.|
|Polito J,Toledo A,Shapiro L,Early detection of systemic Degos disease (DD) or malignant atrophic papulosis (MAP) may increase survival (abstract)Year: 2010San Antonio, TX: American College of Gastroenterology poster 1205.|
|Sullivan GW,Carper HT,Novick WJ Jr,Mandell GL,Inhibition of the inflammatory action of interleukin-1 and tumor necrosis factor (alpha) on neutrophil function by pentoxifyllineInfect ImmunYear: 1988567172217292838424|
|Chave TA,Varma S,Patel GK,Knight AG,Malignant atrophic papulosis (Degos' disease): clinicopathological correlationsJ Eur Acad Dermatol VenereolYear: 2001151434510.1046/j.1468-3083.2001.00216.x11451321|
Keywords: Malignant atrophic papulosis, Köhlmeier-Degos disease, Degos disease, Etiology, Pathophysiology, Clinical manifestations, Prognosis, Treatment, Review.
Previous Document: Independent and combined effects of acute physiological hyperglycaemia and hyperinsulinaemia on meta...
Next Document: Copolymers of poly(lactic acid) and D-?-tocopheryl polyethylene glycol 1000 succinate-based nanomedi...